E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To demonstrate the non-inferiority of HPV immune response at one month post-dose 3 in Chinese female subjects aged 9-17 years from the current study versus Chinese women aged 18-25 years enrolled in the HPV-039 study (eTrack No. 107638).
Criteria for non-inferiority (one month after the third vaccine dose):
-The objective will be reached if for each HPV antigen (anti-HPV-16 and anti-HPV-18), the upper limit of the 95% confidence interval (CI) for the GMT ratio [GMTs in subjects aged 18-25 years with immunogenicity results at Month 7 who receive HPV-16/18 L1 VLP AS04 vaccine in the HPV-039 study divided by the GMTs of subjects aged 9-17 years who receive HPV-16/18 L1 VLP AS04 vaccine in the HPV-058 study] is below 2.
-This objective will be evaluated in the according-to-protocol (ATP) cohort for immunogenicity
|
|
E.2.2 | Secondary objectives of the trial |
Immunogenicity:
•Seroconversion rates to HPV-16 and HPV-18 as assessed by enzyme-linked immunosorbent assay (ELISA) at Month 7.
Safety and reactogenicity:
•To evaluate the reactogenicity of the HPV-16/18 L1 VLP AS04 and control vaccines in all subjects after each dose.
•To evaluate the safety of the HPV-16/18 L1 VLP AS04 and control vaccines in all subjects, throughout the study period.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subjects who the investigator believes that they or their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
•Healthy Chinese females between and including 9 and 17 years of age at the time of the first vaccination.
•Written informed consent obtained from the parent(s)/LAR(s) of the subject and informed assent obtained from the subject, if appropriate, prior to enrolment.
•Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.
•Subjects must not be pregnant. Absence of pregnancy will be verified with a urine pregnancy test before each vaccination.
•Subjects must be either of non-childbearing potential (e.g. pre-menarcheal or surgically sterilised), or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and agree to continue such precautions for 2 months after completion of the vaccination series.
|
|
E.4 | Principal exclusion criteria |
•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone > 0.5 mg/kg/day or equivalent. Inhaled and topical steroids are allowed.)
•Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e., Days 0-29) the first dose of vaccine.
•Concurrently participating in another clinical study, at any time during the study period (i.e. from Day 0 up to the telephone contact at Month 12), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
•A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.
•Pregnant or breastfeeding. Subjects must be at least three months post-pregnancy and not breastfeeding to enter the study.
•Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the protocol during the study period.
•Previous administration of components of the study vaccine (MPL or AS04 adjuvant).
•History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.
•History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine (e.g. aluminium).
•Hypersensitivity to latex (found in syringe-tip cap and plunger).
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
•Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral/axillary temperature >37.0°C).
•Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evaluation of immune responses to components of the study vaccine: Antibody GMTs (by ELISA) against HPV-16/18 antigens. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
One month after the third dose (Month 7) |
|
E.5.2 | Secondary end point(s) |
•Immunogenicity in terms of the study vaccine antigens at Month 7: HPV-16 and HPV-18 seroconversion at Month 7
•Occurrence of each solicited adverse event during the 7 days after each vaccination and any vaccination:
-Local (any, grade 3) adverse events.
-General (any, grade 3, related) adverse events.
•Occurrence of unsolicited adverse events within 30 days after any vaccination.
-Intensity and relationship to vaccination.
•Occurrence of SAEs throughout the study period (up to the telephone contact at Month 12).
-Intensity and relationship to vaccination.
•Occurrence of medically significant conditions (MSCs) throughout the study period (up to the telephone contact at Month 12) regardless of causal relationship to vaccination and intensity.
-Medically significant conditions are defined as: AEs prompting emergency room or physician visits that are not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that are not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury
•Pregnancies and pregnancy outcomes |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immunogenicity: One month after the third dose (Month 7)
Solicited AEs: Day 0 to Day 6 after each vaccine dose
Unsolicited AEs: Day 0 to Day 29 after each vaccine dose
SAEs, MSCs and pregnancies: Throughout the study period |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Phone contact at Month 12 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |